INmune Bio
INMB
INmune Bio (INMB) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| LUCID CAPITAL MARKETS | Upgraded | Neutral → Buy | $9.00 from $2.00 | Mar 11, 2026 |
| Maxim Group | Maintained | Buy | $8.00 from $30.00 | Jul 2, 2025 |
| BTIG | Downgraded | Buy → Neutral | — | Jul 1, 2025 |
| Scotiabank | Downgraded | Sector Outperform → Sector Underperform | $0.60 from $23.00 | Jul 1, 2025 |
| Maxim Group | Maintained | Buy | $30.00 from $22.00 | Feb 13, 2025 |
| Scotiabank | Maintained | Sector Outperform | $23.00 from $22.00 | Feb 11, 2025 |
| Alliance Global Partners | Initiated Coverage | Buy | $20.00 | Oct 21, 2024 |
| Raymond James | Initiated Coverage | Outperform | $18.00 | Sep 27, 2024 |
| Scotiabank | Initiated Coverage | Sector Outperform | $22.00 | Aug 22, 2024 |
Frequently asked questions
What is the latest analyst rating on INMB?
On Mar 11, 2026, LUCID CAPITAL MARKETS upgraded INmune Bio to Buy with a price target of $9.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.